Cargando…

Higher recipient pre‐transplant FOXP3 mRNA expression is associated with acute leukaemia relapse after HSCT

The effect of higher FOXP3 mRNA expression by recipient pre‐transplant CD4+ T cells on leukaemia relapse was analysed in a series of 106 patients who received allogeneic haematopoietic stem cell transplantation after myeloablative conditioning with or without antithymocyte globulin (ATG) due to acut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobsen, Niels, Frisch, Tina, Keiding, Niels, Heilmann, Carsten, Sengeløv, Henrik, Madsen, Hans O., Dickmeiss, Ebbe, Ryder, Lars P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421961/ https://www.ncbi.nlm.nih.gov/pubmed/36051013 http://dx.doi.org/10.1002/jha2.438

Ejemplares similares

High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation
por: Jacobsen, Niels, et al.
Publicado: (2021)

1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Reekie, Joanne, et al.
Publicado: (2020)

Biological and Genetic Aspects of Donor-Recipient Matching in HSCT
por: Lange, Andrzej, et al.
Publicado: (2012)

Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients
por: Machado, Clarisse MARTINS, et al.
Publicado: (2020)

Fusarium infection manifesting as toe cellulitis in HSCT recipient
por: Malkiel, Sarah, et al.
Publicado: (2022)

Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival
por: Nygaard, Marietta, et al.
Publicado: (2018)

Localized Relapse of Primary Plasma Cell Leukaemia in the Central Nervous System
por: Eskelund, Christian W., et al.
Publicado: (2015)

Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Kielsen, Katrine, et al.
Publicado: (2018)

Continuous non-invasive monitoring of the skin temperature of HSCT recipients
por: van Vliet, Maarten, et al.
Publicado: (2009)

Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review
por: Hiskey, Lisa, et al.
Publicado: (2022)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Clostridium difficile Infection in Solid Organ and Haematopoietic Stem Cell Transplant Recipients
por: Ilett, Emma Elizabeth, et al.
Publicado: (2017)

Insulin-Like Growth Factor Gene Polymorphisms Predict Clinical Course in Allogeneic Hematopoietic Stem Cell Transplantation
por: Ebbesen, Maria, et al.
Publicado: (2020)

Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis
por: Giedraitiene, N., et al.
Publicado: (2022)

Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
por: Schierbeck, Frederikke, et al.
Publicado: (2022)

452 Pseudo-Outbreak of Fulminant Toxoplasmosis in Hematopoietic Stem Cell Transplant [HSCT] Recipients
por: Isa, Flonza, et al.
Publicado: (2014)

Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation
por: Minculescu, Lia, et al.
Publicado: (2020)

Deciphering the biology of KIR2DL3(+) T lymphocytes that are associated to relapse in haploidentical HSCT
por: David, Gaëlle, et al.
Publicado: (2021)

Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
por: Santos, Paulo Sérgio da Silva, et al.
Publicado: (2023)

Dental consensus on HSCT – Part II: dental Care during HSCT
por: Gobbi, Marcella Ferreira, et al.
Publicado: (2023)

CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
por: Jaskula, Emilia, et al.
Publicado: (2012)

332. Phaeohyphomycosis Due to Scopulariopsis brumptii in a Hematopoietic Stem Cell Transplant (HSCT) Recipient
por: Syed, Sadia, et al.
Publicado: (2018)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Furuno, Jon P, et al.
Publicado: (2017)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO)
por: Daudt, Liane Esteves, et al.
Publicado: (2022)

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation
por: Lucchini, Giovanna, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report
por: Wang, Jin, et al.
Publicado: (2014)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation
por: Minculescu, Lia, et al.
Publicado: (2019)

Polyclonal gammopathy after BKV infection in HSCT recipient: a novel trigger for plasma cells replication?
por: Maximova, Natalia, et al.
Publicado: (2015)

1411. Risks and Outcomes of Adenovirus Disease in Pediatric HSCT Recipients –Comparison of Current Antiviral Treatment Options
por: Thomas, Sanya J, et al.
Publicado: (2020)

Effects of Exercise Interventions on Immune Function in Children and Adolescents With Cancer and HSCT Recipients - A Systematic Review
por: Beller, Ronja, et al.
Publicado: (2021)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

Pulmonary Complications Associated with HSCT
por: Kapadia, Malika, et al.
Publicado: (2017)

Immunogenicity of Inactivated Varicella Zoster Vaccine (ZV(IN)) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients
por: Boeckh, Michael, et al.
Publicado: (2017)

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis
por: Fucile, Carmen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r3u70h9vneei1129km5eakq76l